You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 石藥集團盤中上漲5%,報於9.15港元

2022年3月23日15時2分,石藥集團(HK01093)盤中上漲5%,報於9.15港元,成交額達3.8億港元,換手率達到0.34%。

3月22日訊,石藥集團(01093.HK)公佈,集團附屬上海津曼特生物科技有限公司的1類新藥JMT103用於治療不可切除或手術困難的骨鉅細胞瘤關鍵臨牀試驗達到預設終點。

3月23日,野村:維持石藥集團(01093)“買入”評級,目標價升至12.32港元。2月10日,光大證券:石藥集團(01093)當前估值具吸引力,維持“買入”評級。1月24日,光大證券:維持石藥集團(01093),“買入”評級,股權激勵激發活力。

最新的財務數據顯示,公司於2021年3季度,營業收入68.19億人民幣,淨利潤12.88億人民幣;營業收入同比增加2.93%,毛利潤同比增加2.24%,淨利潤同比增加5.17%。

盈立趨勢長盈模型最近一次交易信號,2022年3月17日出現關注信號,觸發價格爲8.8699港元(信號僅供參考)。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account